The Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry is expected to reach a valuation of US$ 39.5 Bn in 2028, with demand growing at an average CAGR of 4.7% from 2022 to 2028. In 2022, the target market is set to reach an estimated US$ 30.04 Bn. An increasingly high preference for minimally invasive surgeries will fuel the demand for the benign prostatic hyperplasia (BPH) prostate treatment market during the forecast period.
The rising incidences of benign prostatic hyperplasia have made significant contributions to the target market. The cases of BPH are expected to continue to rise during this period of observation and with more and more patients preferring minimally invasive procedures, the market for benign prostatic hyperplasia (BPH) prostate treatment looks at bright market prospects over the next few years. In addition, the rising geriatric population of the world also contributes to the BPH treatment market growth.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1664
The increasing cases of benign prostatic hyperplasia (BPH) along with a surge in preference for minimally invasive surgeries are primary growth drivers of the target market. Furthermore, the growing popularity of Ayurveda, especially in South Asian countries, will generate more growth-inducing opportunities for the BPH treatment market. Due to all of these considerations, the target market observed a surge in growth rate as it rose to a CAGR of 3.7% from 2013 to 2021.
Heightened emphasis on healthcare, a growing geriatric population, degenerating lifestyle, poor dietary habits, hereditary inheritance of the disease, advancing research and development, and better availability of treatment procedures are some of the prominent factors that positively influence the BPH treatment market growth during the forecast period.
“Rising adoption of minimally invasive procedures coupled with rising incidences of benign prostatic hyperplasia will augment the global growth of the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry over the forecast period,” says an FMI analyst.
Key Takeaways:
- High costs and side effects associated with BPH drugs may stymie market growth.
- North America will account for the dominant portion of the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry share.
- The growing geriatric population coupled with increasing cases of BPH drive the market in the U.S.
- Ayurveda medicines for BPH will present lucrative opportunities in India.
- Institutional sales channel accounts for 64.7% of the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry share.
Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1664
Competitive Landscape
Pfizer Inc., NxThera Inc., NeoTract Inc., Sanofi S.A, GlaxoSmithKline Plc., Allergan Plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eli Lily & Company, and Cardinal Health Inc., among others, are some of the major players in the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry profiled in the full version of the report.
Leading market players are focusing on increasing investment in research and development activities. These participants are keen on offering new treatment options to patients.
More Insights into Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry Report
In its latest report, FMI offers an unbiased analysis of the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry, providing historical data from 2013 to 2021 and forecast statistics for 2022 to 2028. To understand the global market potential, growth, and scope, the market is segmented based on treatment type (BPH drugs (alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonist (MRA), combination drug), BPH devices (prostatic stents, suture base implant systems, transurethral RF thermal therapy devices)), distribution channel (institutional sales (hospitals, ambulatory surgical clinics, specialty clinics), retail sales (retail pharmacies, drug stores), online pharmacies), and region.
According to the latest FMI reports, based on segmentation, the institutional sales segment leads the market. This segment accounts for 64.7% of the overall market share owing to the rising demand for minimally invasive surgeries. The retail sales segment accounts for 26.7% while the online pharmacies segment holds 8% of the Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry share.
Based on region, the benign prostatic hyperplasia (BPH) prostate treatment market in the United States will exhibit impressive growth during 2022-2028. The rising geriatric population coupled with increasing cases of BPH propel the target market growth in this country. Growth in research and development activities will further aid the target market growth during the projected period. Besides, India’s benign prostatic hyperplasia (BPH) prostate treatment market, too, will present notable growth. This is due to the popularity of Ayurveda as well as a surge in BPH cases. Thus, these two countries will demonstrate significant growth in the benign prostatic hyperplasia (BPH) prostate treatment market during the forecast period.
Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/1664
Key Segments of Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry Survey
Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry by Treatment Type:
- BPH Drugs
- Alpha Blockers
- 5-Alpha Reductase Inhibitors
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Muscarinic Receptor Antagonist (MRA)
- Combination Drug
- BPH Devices
- Prostatic Stents
- Suture Base Implant Systems
- Transurethral RF Thermal Therapy Devices
Global Benign Prostatic Hyperplasia (BPH) Prostate Treatment Industry by Distribution Channel:
- Institutional Sales
- Hospitals
- Ambulatory Surgical Centres
- Specialty Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
